Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Alcon’s IOL Faces Probe by CDSCO
The Central Drugs Standard Control Organisation (CDSCO) has formed a committee to investigate allegations of quality issues with an intraocular lens (IOL) supplied by Alcon. The Swiss-American company specializes in eye care products, including lenses for cataract surgery. Specifics of…
Eyenovia Pediatric Myopia Trial Falls Short
Eyenovia has announced that its Phase 3 CHAPERONE study, aimed at treating pediatric progressive myopia, failed to meet its primary endpoint. The trial evaluated the company’s proprietary drug-device combination using low-dose atropine delivered via the Optejet platform. A review by…
Cequa Shows Positive Phase 4 Results for Dry Eye
Sun Pharmaceutical has shared new Phase 4 clinical trial data, showcasing the efficacy of Cequa (cyclosporine ophthalmic solution) 0.09% in treating dry eye disease (DED). The results reveal that Cequa provides sustained improvements in patients whose symptoms were inadequately managed…
Bausch + Lomb Recycles 94M Eye Care Waste Units
Bausch + Lomb has announced a major milestone in its sustainability efforts. Through its exclusive recycling initiatives—ONE by ONE Recycling and Biotrue Eye Care Recycling programs—the company has collected 94,119,275 units of used contact lenses, eye care products, and lens…
MediPrint Announces Positive Results for Glaucoma Lens
MediPrint Ophthalmics has revealed positive findings from its Phase 2b clinical trial for LL-BMT1, a 3D-printed, drug-eluting contact lens designed to treat mild to moderate glaucoma. These results, presented by Ian Ben Gaddie, OD, FAAO, at the American Academy of…
Atsena & Nippon Shinyaku Partner on ATSN-101
Atsena Therapeutics, Inc. and Nippon Shinyaku Co., Ltd. have entered an exclusive licensing agreement to advance and commercialize ATSN-101, an investigational gene therapy for Leber congenital amaurosis type 1 (LCA1), in both the United States and Japan. ATSN-101 is designed…
Top 15 International Ophthalmology Congresses in 2024
As the field of ophthalmology continues to advance, a plethora of international congresses offer opportunities for professionals to explore the latest innovations, share insights, and foster collaborations. Here is a comprehensive list of the top 15 international ophthalmology conferences scheduled…
Formosa: Positive Phase 3 Results for APP13007 in China
Formosa Pharmaceuticals recently announced the completion of CPN-303, a Phase 3 clinical trial conducted in Chinese cataract surgery patients to evaluate APP13007 (GPN00833). This trial, managed by Formosa’s licensee Grand Pharma (0512.HK), demonstrated positive top-line results, showcasing APP13007’s effectiveness in…
Neurotech FDA Update on NT-501 MacTel Treatment| OBN
Neurotech Pharmaceuticals has released an update regarding its biologics license application (BLA) for NT-501 (revakinagene taroretcel), a treatment designed for macular telangiectasia type 2 (MacTel). The U.S. Food and Drug Administration (FDA) has recently extended the Prescription Drug User Fee…
FDA Fast Tracks FLQ-101 for Retinopathy of Prematurity
The U.S. FDA has granted fast track designation to FLQ-101, FELIQS’ oral and intravenous solution targeting retinopathy of prematurity (ROP). This designation will accelerate the regulatory review process for FLQ-101, a promising treatment for a condition currently lacking approved preventative…